Hip Replacement — Cost, Top Hospitals & Success Rates | MyMedicPlus

Total hip replacement (THR), also called total hip arthroplasty, is a surgical procedure in which the damaged surfaces of the hip joint — the femoral head and the acetabulum (socket) — are removed and replaced with prosthetic components made of metal, ceramic, or polyethylene. The hip is a ball-and-socket joint; in severe arthritis the protective articular cartilage wears away, causing bone-on-bone contact, intense pain, stiffness, and loss of function. The prosthesis recreates smooth, pain-free joint mechanics and allows restoration of normal gait. Modern implants consist of a metal or ceramic femoral stem inserted into the femur, a femoral head (ball) of ceramic or metal, a metal shell pressed into the acetabulum, and a polyethylene or ceramic acetabular liner. Fixation is achieved either with bone cement (cemented) or by bone ingrowth into a porous-coated surface (cementless), or a hybrid of both. Minimally invasive approaches using 2 smaller incisions or the direct anterior approach reduce muscle trauma, enable faster recovery, and improve early functional outcomes. Surgery is performed under general or spinal anaesthesia and takes 1–2 hours. Hip replacement is one of the most successful and cost-effective procedures in medicine.

Total hip replacement is most commonly performed for end-stage osteoarthritis of the hip — the progressive breakdown of articular cartilage causing bone-on-bone friction, pain, and functional disability. Other major indications include rheumatoid arthritis and other inflammatory arthropathies that destroy joint cartilage; avascular necrosis (osteonecrosis) of the femoral head caused by steroid use, alcohol, trauma, or sickle cell disease; hip fracture in elderly patients (displaced femoral neck fracture) where hemiarthroplasty or total hip replacement is preferred over internal fixation; post-traumatic arthritis following previous hip injuries or fractures; and hip dysplasia — abnormal hip joint development causing early arthritis. Less common indications include Paget's disease of bone, ankylosing spondylitis, and benign or malignant tumours requiring resection and reconstruction. Revision hip replacement is performed when a primary prosthesis fails due to aseptic loosening, wear, instability, infection, or periprosthetic fracture.

Hip replacement is recommended when severe hip pain and disability significantly impair quality of life despite 3–6 months of conservative management including analgesics, NSAIDs, physiotherapy, weight loss, and corticosteroid injections. Candidates typically have radiographic evidence of advanced joint space narrowing or destruction, pain at rest or at night, and inability to perform daily activities such as walking more than a block or climbing stairs. Pre-operative assessment includes hip X-rays (AP pelvis and lateral hip), blood tests, cardiac evaluation, and assessment of bone quality and acetabular anatomy. Most patients are aged 55–80, but the procedure is increasingly performed in younger active patients with better-quality implants. Contraindications include active joint or systemic infection, severe medical co-morbidities making anaesthesia prohibitive, significant neurological conditions affecting the limb, morbid obesity (BMI >40 is a relative contraindication), and absence of bone stock to support the prosthesis. Patients must be able to participate in post-operative rehabilitation.

Treatment options are tailored to individual patient needs based on disease severity, comorbidities, patient preference, and clinical guidelines. The treating physician will discuss all available options and recommend an approach based on the complete clinical assessment.

First-line treatment follows established evidence-based protocols with well-documented efficacy and safety profiles. This may involve pharmacological therapy with single or combination agents, procedural intervention using minimally invasive or open techniques, or a combination approach integrating multiple treatment modalities.

Second-line options are considered when primary treatment fails to achieve therapeutic targets or is not tolerated. These include alternative agents within the same drug class, different treatment modalities, or escalation to more intensive therapy at specialist centres.

Emerging treatments available through clinical trials or specialist referral include novel targeted agents, biological therapies, advanced procedural techniques, and gene therapy approaches for selected conditions. Patients are encouraged to discuss eligibility for clinical trials with their specialist. Treatment intensity is regularly reassessed and adjusted based on clinical response, ensuring optimal outcomes while minimising unnecessary exposure to treatment-related risks.

The selection of treatment approach follows a systematic assessment of clinical factors, patient preferences, and risk-benefit considerations. Evidence-based guidelines from professional societies including WHO, NICE, and relevant specialty organisations inform treatment selection and protocol design.

Combination treatment strategies are increasingly favoured where multiple modalities provide synergistic benefit. The sequence and intensity of treatment components are titrated based on patient response at defined assessment intervals. Patients not responding adequately to initial treatment undergo structured reassessment to identify alternative approaches or combination strategies.

Personalised medicine approaches using biomarker profiling and genetic analysis are emerging as tools to predict treatment response and guide individualised treatment selection in eligible patients. Multidisciplinary team review ensures all relevant clinical expertise informs treatment decisions for complex cases.

Total hip replacement is one of the most successful elective surgical procedures with outstanding long-term outcomes. Over 95% of patients report significant pain relief and improved function by 3 months post-operatively. Patient satisfaction exceeds 90% at 5-year follow-up. Modern implants have implant survival rates of 90–95% at 15–20 years, meaning most patients never require revision surgery. The procedure restores the ability to walk normally, climb stairs, drive, and participate in low-impact recreational activities such as swimming, cycling, and golf. Minimally invasive approaches accelerate recovery, with many patients walking the day of surgery and discharged within 2–3 days. Hip replacement also improves cardiovascular health by enabling increased physical activity, reduces depression associated with chronic pain, and lowers mortality risk in elderly patients with hip fractures. Ceramic-on-ceramic and ceramic-on-polyethylene bearing couples offer minimal wear and are well-suited for younger patients.

Hip replacement is safe when performed at accredited centres, but risks include: deep vein thrombosis (DVT) in 1–3% of patients despite prophylaxis; pulmonary embolism in 0.1–0.5%; prosthetic joint infection in 0.5–2%, the most feared complication requiring explantation and staged re-implantation; hip dislocation in 1–3%, more common in posterior approach; leg length discrepancy (<1 cm in most cases); periprosthetic fracture (0.1–0.4% intraoperatively); aseptic loosening requiring revision at 5–10% over 15 years; nerve injury (sciatic or femoral) in 0.5–2% causing foot drop or thigh numbness; heterotopic ossification (abnormal bone formation around the joint) in 5–15%, usually mild; and implant wear debris causing osteolysis. General anaesthesia risks include cardiovascular and pulmonary complications, particularly in elderly patients. Blood transfusion is required in 5–15% of cases though rates are reduced with tranexamic acid protocols.

Structured follow-up is essential to optimise treatment outcomes and ensure early identification of complications or disease recurrence. The follow-up schedule is individuialised based on treatment type, disease characteristics, and patient-specific factors.

Standard follow-up scheduling involves: early post-treatment review at 2-4 weeks to assess initial response and manage any early side effects; monthly assessments for the first 3 months to monitor treatment response and titrate therapy as needed; quarterly review for the remainder of the first year; and annual long-term follow-up for stable patients.

Each follow-up visit includes clinical examination, relevant laboratory testing as indicated by the treatment protocol, imaging studies at defined intervals based on condition-specific guidelines, and assessment of patient-reported outcomes and quality of life.

Patients are provided with clear guidance on symptoms requiring urgent medical review between scheduled appointments, including signs of serious complications or disease progression. Remote consultation options including telephone and video review facilitate access to specialist advice between face-to-face appointments. Long-term surveillance continues indefinitely for chronic conditions, with frequency adjusted based on individual risk profile and clinical response.

Hip replacement in India costs USD 4,500–8,000 for a total hip replacement at top-tier JCI-accredited hospitals (Apollo, Fortis, Medanta, Kokilaben), inclusive of surgeon fees, implant (including premium ceramic or uncemented components), anaesthesia, 4–5 nights hospitalisation, and physiotherapy sessions. This represents savings of 70–80% compared to US prices. In Thailand, hip replacement costs USD 8,000–15,000; Turkey USD 6,000–12,000; Mexico USD 6,000–11,000; Singapore USD 12,000–25,000. In the USA, total hip replacement costs USD 35,000–65,000 without insurance. UK private treatment costs GBP 12,000–20,000. The implant brand (Zimmer Biomet, Stryker, DePuy, Smith & Nephew) influences costs; major Indian hospitals stock internationally approved prostheses. Medical tourist packages in India typically include airport transfer, accommodation, interpreter, and post-operative physiotherapy.

Treatment costs vary substantially by geographic location, healthcare setting, facility tier, and individual case complexity. Understanding cost factors helps patients make informed decisions about their care, particularly when considering medical tourism or private healthcare options. In India,

Alternative treatment approaches are considered when first-line treatment is contraindicated, not tolerated, or fails to achieve therapeutic targets. The range of alternatives depends on the specific condition and patient circumstances.

Conservative management with watchful waiting and close monitoring is appropriate for mild or asymptomatic presentations where the natural history is favourable and intervention risks outweigh expected benefits. Regular surveillance allows timely escalation when clinical criteria for active treatment are met.

Non-pharmacological approaches including physiotherapy, occupational therapy, dietary optimisation, and structured lifestyle modification programmes form the foundation of management for many conditions. These interventions reduce symptom burden, improve functional capacity, and may delay or eliminate the need for pharmacological or procedural treatment.

Alternative pharmacological approaches include agents from different drug classes with different mechanisms of action, dosing strategies, or delivery routes. Clinical trials evaluating novel agents may offer access to emerging therapies not yet in routine clinical practice.

Surgical alternatives range from minimally invasive endoscopic or laparoscopic approaches to open surgery, each appropriate for different clinical scenarios. Complementary and integrative medicine approaches including acupuncture, herbal medicine, and mind-body therapies may provide symptomatic benefit for some patients as adjuncts to conventional care, though evidence quality varies and potential interactions with conventional treatment should be discussed with a qualified practitioner.